Format

Send to

Choose Destination
See comment in PubMed Commons below
Immunol Allergy Clin North Am. 2010 May;30(2):221-36. doi: 10.1016/j.iac.2010.01.002.

Bone marrow transplantation and alternatives for adenosine deaminase deficiency.

Author information

1
Centre for Immunodeficiency, Molecular Immunology Unit, UCL Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK. h.gaspar@ich.ucl.ac.uk

Abstract

Adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID) comprises approximately 10% to 15% of all cases of SCID. The clinical effects of ADA deficiency are manifest most dramatically in the immune system, where it leads to severe lymphopenia. Although hematopoietic stem cell transplantation remains the mainstay of treatment for ADA-deficient SCID, 2 other treatment options are available, namely enzyme replacement therapy with PEG-ADA and autologous hematopoietic stem cell gene therapy. In this article the author reviews the available data on treatment by these different options, and offers an overview on when each of the different treatment options should be used.

PMID:
20493398
DOI:
10.1016/j.iac.2010.01.002
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center